Skip to main content

What the FDA labels say about taking them together

Octreotide and telotristat

Telotristat's FDA label of August 6, 2026 names octreotide in its drug interactions section; the octreotide labels PlainMeds reads (4) do not name telotristat. The telotristat label: “Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite.”

Check it at the source: the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation); the telotristat FDA label on DailyMed (effective August 6, 2026).

What does the octreotide label say about telotristat?

Octreotide's label (effective July 22, 2026) and its 3 other brand-application labels do not name telotristat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed

What does the telotristat label say about octreotide?

Telotristat label, drug interactions

Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite.

Source: FDA drug label (Xermelo), TerSera Therapeutics LLC, effective August 6, 2026 (SPL set a4ac9d62-887c-4c8f-b04d-a5f31cec7c86), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Octreotide generic labelers
0Telotristat generic labelers
OctreotideTelotristat
Labeled forDiarrheaDiarrhea
Boxed warningNoNo
Pharmacy cost (NADAC)$2.53 per mL 100 mcg/mL vialn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?